32 results about "Cardiac Progenitor Cell" patented technology

A method for treating a subject afflicted with a cardiac disorder, in vivo, comprises (i) inducing differentiation of a progenitor cell, in vitro, to a cardiogenic cell; and (ii) administering a therapeutically effective amount of the cardiogenic cell of step (i) to the subject, thereby treating the cardiac disorder in the subject. This invention further provides related articles of manufacture and methods.

The presently-disclosed subject matter relates to compounds of the formula:

and methods for use thereof. The presently-disclosed subject matter relates methods of selectively differentiating a stem cell, and methods of screening for compounds useful for enhancing terminal differentiation of committed cardiac progenitor cells.

The present invention relates to a method for the isolation of subpopulations of cardiac progenitor cells from a heart tissue sample, the population thus obtained and the related uses in the medical field for the cell therapy or cardiac cell and/or tissue transplantation field.

The invention provides a method for directly re-programming heart progenitor cells based on endogenous gene transcriptional activation. The method has better operation feasibility and theory creativity. For the first time, through a CRISPR/Cas9 system, endogenous heart development relevant transcription factors GATA4, HAND2, MEF2C, TBX5 and MEIS1 are activated, human foreskin fibroblasts are induced to be re-programmed into the heart progenitor cells having the potential of being disintegrated towards cardiac muscle cells, smooth muscle cells and endothelial cells, a seed cell source is provided for cardiovascular disease model construction, new medicine screening and myocardial regeneration, and besides, a novel apparent cell re-programming theory and connotation are enriched.

Provided is a method of inducing cardiac progenitor cells or cardiomyocytes from fibroblasts. The present invention provides a method for producing cardiac progenitor cells, comprising introducing one cardiac reprogramming factor into fibroblasts, or a method for producing cardiomyocytes, comprising introducing three cardiac reprogramming factors into fibroblasts.

An improvement to the GiWi protocol for differentiating human pluripotent cells to developmentally mature cardiomyocytes includes a step of activating innate immunity in mesoderm stage cells in the in vitro differentiation culture. When the mesoderm cells, which are precursors to cardiac progenitor cells, are primed by exposure to an activator of innate immunity, a population of cardiomyocytes is generated that is more developmentally mature than is generated in the GiWi protocol without the primed step. Also provided herein are in vitro ventricular conductive microtissues and isolated, in vitro populations of ventricular conduction system-like cells and methods for making the same.

The invention provides one or more of miR-290 family and Lin28a modified cardiac progenitor cell based therapies for the treatment of myocardial infarction. Exosomes derived from one or more of miR-290 family and Lin28a modified cardiac progenitor cells can also be used in cardiac therapy.

Provided is a method of inducing cardiac progenitor cells or cardiomyocytes from pluripotent stem cells.

The present invention provides a method for producing cardiac progenitor cells from pluripotent stem cells, comprising expressing Tbx6 in the pluripotent stem cells. Moreover, the present invention provides a method for producing cardiomyocytes from pluripotent stem cells, comprising: a step of inducing cardiac progenitor cells from pluripotent stem cells, comprising expressing a Tbx6 gene in the pluripotent stem cells; and a step of inducing cardiomyocytes from the cardiac progenitor cells induced in the above step, comprising suppressing the expression of the Tbx6 gene.

Provided are a composition for cell transplant and a method for cell transplant, both of which enable a myocardial tissue to favorably retain cardiac myocytes and/or cardiac progenitors and can improve the persistence and proliferation of transplanted cells. The composition for cell transplant of the present invention is a composition for cell transplant, containing cells and an aqueous solution containing a protein (A), the cells including a cardiac myocyte and/or a cardiac progenitor, the protein (A) having a degree of hydrophobicity of 0.2 to 1.2, the protein (A) containing a polypeptide chain (Y) and/or a polypeptide chain (Y′), the protein (A) containing 1 to 100 polypeptide chains as a total of the polypeptide chain (Y) and the polypeptide chain (Y′), the polypeptide chain (Y) being a polypeptide chain having 2 to 100 continuous amino acid sequences (X), the amino acid sequence (X) having any one of a VPGVG sequence (1) corresponding to an amino acid sequence of SEQ ID NO: 1, a GVGVP sequence (2) corresponding to an amino acid sequence of SEQ ID NO: 2, a GPP sequence, a GAP sequence, and a GAHGPAGPK sequence (3) corresponding to an amino acid sequence of SEQ ID NO: 3, the polypeptide chain (Y′) being a polypeptide chain having a structure in which 0.1 to 5% amino acid residues in the polypeptide chain (Y) are replaced by a lysine residue and/or an arginine residue and including 1 to 100 residues as a total of the lysine residue and the arginine residue.